CoStim Pharmaceuticals

What CoStim Pharmaceuticals does

CoStim Pharmaceuticals Inc. is a privately held, development-stage biotechnology company founded in 2011 and headquartered in Boston, Massachusetts, focused on developing antibody agents for the treatment of cancer. The company operates with a small team of 11-50 employees and is led by founder Luke Evnin. Its core business is the research and development of therapeutic antibodies, targeting oncology indications through traditional biotech drug discovery approaches. The company was founded by Luke Evnin and has attracted institutional biotech investors, including Atlas Venture, MPM Capital, Johnson & Johnson Development Corporation, and Partners Innovation Fund, which collectively provided approximately $22M in a 2013 Series A financing.

The company's business model is consistent with a pre-commercial biopharmaceutical developer: revenue is not yet generated from approved products, and the value creation thesis centers on advancing antibody candidates through preclinical and clinical development toward potential licensing, partnership, or acquisition events with larger pharmaceutical companies. CoStim has not disclosed specific pipeline candidates, clinical trial milestones, or regulatory filings in the available data, and no public revenue or licensing income has been reported. The company's competitive positioning depends on its proprietary antibody intellectual property, its scientific founders and team, and its investor syndicate's ability to provide follow-on financing or facilitate strategic transactions.

A material data integrity note: the source material aggregates information that appears to describe a different entity (Costim Real Estate, an Italian urban regeneration development company based in Bergamo). This analysis is grounded in the firmographic definition of CoStim Pharmaceuticals as a Boston-based cancer antibody biotech, supported by consistent funding round details and founder identity. The Italian real estate data is not relevant to CoStim Pharmaceuticals' biotech operations and has been excluded from the analytical conclusions above.

Name

CoStim Pharmaceuticals

Legal name

Costim Real Estate S.r.l.

Website

https://costim.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

CoStim Pharmaceuticals is a privately held Boston-based biotechnology company founded in 2011 that develops antibody therapeutic agents for the treatment of cancer, with operations supported by 11-50 employees and early-stage institutional venture financing.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Cancer antibody therapeutics
• Oncology drug development
• Biopharmaceutical research
• Monoclonal antibody therapy
• Immunotherapy drug discovery

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Urban Development and Construction: Development and construction of urban regeneration projects including residential, commercial, hospitality, and mixed-use developments. Revenue generated through project sales, development fees, and construction coordination services.
2. Property Management Services: Ongoing management of services and maintenance for completed districts, including contract management, technical maintenance of systems, and space allocation services.
3. Project Management Services: Overseeing construction projects from design to delivery, ensuring quality, timelines, and costs through advanced digital tools and rigorous project management approaches.
4. PPP Project Development: Development of public-private partnership projects where the company collaborates with government entities to regenerate urban areas, with revenue derived from project development and ongoing management fees.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

CoStim Pharmaceuticals Inc. is a biotechnology company that develops antibody agents for the treatment of cancer. The company focuses on oncology biopharmaceutical research, building therapeutic antibody candidates intended to address cancer indications.

Product overview

Costim Real Estate operates as a development company with an integrated ecosystem of four business units: Costim DEV (strategic development), Costim PM (project management), Costim MC (management company), and Costim XP (digital experience). The company's flagship offering is the ChorusLife 'human smart district' concept, which integrates technology and human well-being into urban regeneration projects. Projects include realized developments like ChorusLife Bergamo, and ongoing projects including Linate Airport District, ChorusLife Pietra Ligure, ChorusLife Trieste, and Stadio Cagliari.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer antibody therapeutic agents Antibody-based therapeutic agents intended for the treatment of cancer, developed by CoStim Pharmaceuticals as a development-stage biotechnology company.

Quantifiable outcome

• 70,000 sqm of territory transformed and 150,000 sqm total area redeveloped (ChorusLife Bergamo)
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators7 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Zymeworks: Clinical-stage biotech developing multifunctional antibody therapeutics for cancer, including bispecific antibodies. Comparable in therapeutic area focus and platform-based antibody development strategy.
• Werewolf Therapeutics: Clinical-stage oncology biotech developing conditionally activated biologics including INDUKINE molecules for cancer immunotherapy. Comparable in therapeutic focus (cancer immunotherapy), development stage, and biotech profile.
• Mersana Therapeutics: Clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) for cancer treatment. Comparable as a small-cap antibody oncology platform company with a single therapeutic area focus and similar capital requirements.
• Compass Therapeutics: Clinical-stage oncology biotech developing antibody-based therapeutics, including bispecific antibodies for cancer. Boston-based, comparable in therapeutic area, platform approach, and company profile.
• Inhibrx (acquired by Sanofi): Clinical-stage biotech developing antibody-based therapeutics for oncology and rare diseases (acquired by Sanofi in 2024). Comparable as a small-cap antibody platform company; demonstrates exit pathways for similar players.
• CytomX Therapeutics: Clinical-stage oncology biotech developing antibody-based therapeutics including Probody therapeutics. Highly comparable as a small-cap, Boston-area (originally San Francisco) antibody oncology company targeting solid tumors with similar capital intensity and pipeline concentration.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs). Comparable as a Bay Area antibody oncology biotech with platform-based approach to cancer immunotherapy.
• Macrogenics: Clinical-stage biotech developing antibody-based therapeutics for cancer, including immune checkpoint agonists and bispecific antibodies. Directly comparable in therapeutic focus (antibody oncology), pipeline strategy, and target patient population.

Broad incumbents

• ImmunoGen (AbbVie): Pioneer in antibody-drug conjugates (ADCs) for cancer, recently acquired by AbbVie. Comparable as a larger, more mature antibody oncology company that built significant pipeline value and demonstrated a viable exit pathway for the segment.
• Astellas Pharma: Global pharmaceutical company with a significant antibody oncology franchise, including ADCs (Padcev, Xospata) and emerging immuno-oncology programs. Comparable as a strategic acquirer and competitor in the antibody oncology space.

Market position

Strengths4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/costim
• Instagraminstagram.com/costim.re

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoStim Pharmaceuticals